Loading clinical trials...
Loading clinical trials...
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
ITB-Med LLC
NCT05753930 · Kidney Transplantation in Highly Sensitized Patients
NCT04128189 · Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, and more
NCT06568549 · Kidney Transplantation, Mycophenolate Mofetil
NCT04870437 · Kidney Transplantation
NCT07415421 · Hyperparathyroidism, Kidney Transplantation Recipients
Innsbruck Medical University
Innsbruck
University of Vienna
Vienna
Hospital Clinic de Barcelona
Barcelona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions